Biorem Inc AI Stock Analysis
Want to see TSE:BRM full AI Analyst Report?
Biorem Inc (BRM) AI Stock Analysis
Biorem Inc
(TSXV:BRM)
The company's operational turnaround and strong balance sheet are significant strengths, but the overall score is constrained by a severe cash conversion problem where reported profits are not translating into cash flow. Positive technical momentum and a low P/E ratio provide support, though the stock is nearing overbought levels.
Biorem Inc (BRM) vs. iShares MSCI Canada ETF (EWC)
- Market Cap
- CAD 81.66M
- Dividend Yield
- ―
- Average Volume (3M)
- 17.23K
- Price to Earnings (P/E)
- 9.7
- Beta (1Y)
- 0.27
- Revenue Growth
- 61.47%
- EPS Growth
- 257.78%
- Country
- Canada
- Employees
- 57
- Sector
- Industrials
- Sector Strength
- 63
- Industry
- Industrial - Pollution & Treatment Controls
Biorem Inc Business Overview & Revenue Model
Company Description
BioRem Inc. is a clean technology engineering firm specializing in the development, manufacturing, and global distribution of environmental air purification systems. These systems are engineered to combat a range of airborne contaminants, including f...
How the Company Makes Money
Biorem makes money primarily by selling air emissions control projects and related equipment to customers that need odor and VOC control. Revenue is generated from (1) engineered system sales, where Biorem designs and supplies biotrickling filter/bio...
Biorem Inc Financial Statement Overview
Summary
Strong income statement and balance sheet, marked by robust revenue growth, expanding margins, and successful deleveraging. However, the overall financial health is weighed down by a critical cash flow weakness, as TTM operating cash flow to net income is just 0.02, indicating poor earnings quality.
Income Statement
82Very PositiveBalance Sheet
78PositiveCash Flow
45Neutral| Breakdown | TTM | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 56.08M | 42.36M | 37.42M | 25.17M | 28.86M | 24.48M |
| Gross Profit | 17.89M | 12.59M | 10.06M | 7.02M | 8.76M | 6.24M |
| EBITDA | 10.80M | 7.05M | 4.82M | 3.45M | 2.99M | 2.68M |
| Net Income | 7.75M | 4.82M | 3.04M | 2.18M | 1.61M | 1.30M |
Balance Sheet | ||||||
| Total Assets | 36.22M | 33.58M | 28.51M | 24.08M | 20.73M | 19.17M |
| Cash, Cash Equivalents and Short-Term Investments | 7.94M | 11.50M | 5.21M | 2.29M | 3.78M | 4.47M |
| Total Debt | 2.31M | 2.83M | 3.56M | 4.19M | 4.75M | 5.67M |
| Total Liabilities | 15.82M | 18.65M | 17.89M | 17.36M | 16.21M | 17.20M |
| Stockholders Equity | 20.41M | 14.93M | 10.63M | 6.72M | 4.52M | 1.96M |
Cash Flow | ||||||
| Free Cash Flow | 49.90K | 7.27M | 3.31M | -62.84K | 1.24M | 3.71M |
| Operating Cash Flow | 482.09K | 7.64M | 3.69M | 490.03K | 1.44M | 3.78M |
| Investing Cash Flow | -432.20K | -367.83K | -372.00K | -552.87K | -203.29K | -75.98K |
| Financing Cash Flow | -575.72K | -767.05K | -572.04K | -1.33M | -951.80K | -7.56M |
Biorem Inc Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:BRM, the sentiment is Positive. The current price of 4.60 is above the 20-day moving average (MA) of 4.19, above the 50-day MA of 3.79, and above the 200-day MA of 3.23, indicating a bullish trend. The MACD of 0.26 indicates Negative momentum. The RSI at 68.14 is Neutral, neither overbought nor oversold. The STOCH value of 67.97 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for TSE:BRM.
Biorem Inc Peers Comparison
Overall Rating
TSE:BRM73Outperform
TSE:TMG58Neutral
TSE:GRN54Neutral
TSE:QST42Neutral
TSE:SHRC39Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| 73Outperform | CAD 81.66M | 9.73 | 45.45% | ― | 61.47% | 257.78% | |
| Sector * | 63Neutral | $10.79B | 15.43 | 7.44% | 2.01% | 2.89% | -14.66% |
| 58Neutral | CAD 24.79M | 30.85 | 16.53% | ― | 16.89% | ― | |
| 54Neutral | CAD 27.26M | -6.94 | -17.65% | ― | 4.36% | -263.33% | |
| 42Neutral | CAD 5.55M | -1.72 | -16.34% | ― | -74.07% | -251.51% | |
| 39Underperform | CAD 9.91M | -2.76 | 109.61% | ― | -22.75% | 5.86% |
* Industrials Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| TSE:BRM | Biorem Inc | 4.60 | 2.04 | 79.69% | |
| TSE:SHRC | Sharc International Systems Inc. | 0.06 | -0.01 | -14.29% | |
| TSE:QST | Questor Technology | 0.20 | -0.20 | -50.00% | |
| TSE:TMG | Thermal Energy International | 0.14 | 0.02 | 20.83% | |
| TSE:GRN | Greenlane Renewables | 0.17 | -0.03 | -17.07% |
Biorem Inc Corporate Events
BIOREM Reports Record Third-Quarter Revenue and Earnings
PositiveBIOREM Inc., a clean technology company providing air emissions control systems to municipal and industrial customers, reported record third-quarter results for 2026. Revenue rose 48% year over year to $16.6 million, while net earnings increased to $...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Nov 10, 2026
